%0 Journal Article
%T Cardiovascular Protection of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Type 2 Diabetes Mellitus; Literature Review
%A Ziyad Ali Alsaedi
%A Khalid Mohammed Alahmadi
%A Abdulaziz Zakaria Khan
%A Ezzaddin Mugahed Alrait
%A Mohammed Khaled Al Ghamdi
%A Abdullah Mutrik Alqahtani
%A Hadil Ali Alkahmous
%A Rakan Saleh Alanazi
%A Anas Abdulrhman Aljohani
%A Wessam Ahmed Alsawyan
%A Faisal Ayed Almazariqi
%A Abdullah oudah saeed al jabal
%J International Journal of Pharmaceutical Research and Allied Sciences
%@ 2277-3657
%D 2021
%V 10
%N 2
%R 10.51847/acxDC9hQpC
%P 139-143
%X Diabetes mellitus is a significant risk factor for major adverse cardiovascular events and all-cause mortality. It is essential to control blood glucose levels, but a combination of controlled blood glucose and cardioprotective effect, mortality, and morbidity secondary to diabetes would be significantly reduced. Sodium-glucose co-Transporter 2 inhibitor provides great diabetic control in addition to protection against cardiovascular events, with or without increased cardiovascular risks. This narrative review aims to assess the efficacy and safety of SGLT2i in preventing cardiovascular consequences among patients with diabetes mellitus type-2. A search in the PubMed database was performed for relevant articles using the following Mesh words: Sodium-glucose co-transporter 2 inhibitor, an SGLT2 inhibitor, Cardiovascular protection, Cardiovascular events, myocardial infarction. SGLT-2 inhibitors were found to provide cardiovascular protection and decreased all-cause of death in addition to reasonable glycemic control compared to placebo. Several rare adverse effects were reported, but generally, all of them were affordable and well-tolerated. Further trials are recommended to establish SGLT-2 inhibitors concerning the risk of amputations. 
%U https://ijpras.com/article/cardiovascular-protection-of-sodium-glucose-co-transporter-2-inhibitors-sglt2i-in-type-2-diabetes-b5wx0v5qdncuood